StockNews.AI
TECH
StockNews.AI
19 hrs

Bio-Techne Highlights Progress on Climate, Innovation, and Culture in 2025 Sustainability Report

1. Bio-Techne's report emphasizes sustainability alongside advancing human health. 2. 40% reduction in Scope 1 and 2 emissions through renewable electricity commitment. 3. New board oversight for AI and sustainable practices established. 4. Innovations in diagnostics and life sciences reported to drive market growth. 5. Commitment to employee empowerment and diverse workplace culture highlighted.

7m saved
Insight
Article

FAQ

Why Bullish?

Bio-Techne's sustainability initiatives position it favorably amidst increasing investor focus on ESG.

How important is it?

Sustainability commitment and innovation directly align with market trends and investor preferences in TECH.

Why Long Term?

Sustainable practices and innovation can enhance the company's reputation and sales over time.

Related Companies

MLABILMNAVDR
Company advances transition to renewable electricity and sets a pathway to science-based emissions reductions, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate Sustainability Report, underscoring the company's commitment to advancing human health while protecting the planet. Bio-Techne's 2025 Sustainability Report is available at www.bio-techne.com/about/corporate-and-social-responsibility "As a global innovator in life sciences, our mission is to improve the quality of life by catalyzing advances in science and medicine," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "We recognize that human health and the environment are intrinsically connected. By aligning our science with sustainable business practices, we not only unlock potential for better health outcomes, but also create lasting value for our employees, empower our customers, and strengthen the communities in which we live and work." Highlights from Bio-Techne's 2025 Sustainability Report demonstrate measurable progress and bold commitments, including: Ongoing development and commercialization of breakthroughs in cancer, diabetes, neurodegenerative, autoimmune, and rare diseases—transforming diagnosis and care for millions worldwide. An estimated 40% reduction in Scope 1 and 2 emissions enterprise-wide, driven by the transition to 100% renewable electricity at the company's Minneapolis headquarters.⃰ Commitment to set Scope 1, 2, and 3 greenhouse gas (GHG) reduction targets, with submission for validation to the Science Based Targets Initiative (SBTi) in 2026. Enhanced governance measures, including new Board oversight of artificial intelligence and completion of the first double materiality and climate assessments to guide sustainability priorities. Investment in culture and careers, with development and learning opportunities designed to empower teams under Bio-Techne's EPIC values—Empowerment, Passion, Innovation, and Collaboration Bio-Techne's sustainability initiatives also fuel innovation across its life sciences portfolio, driving advances in cell therapy workflows, proteomic analytical instruments, spatial biology, and precision diagnostics—all developed with increased emphasis on efficiency and resource-conscious design."Our customers trust us to advance science responsibly, and we know that starts with our people," added Kelderman. "This report underscores our commitment to protecting the environment, supporting our employees and communities, and creating a workplace where diverse perspectives drive innovation and lasting impact."The full 2025 Sustainability Report is available in the Corporate and Social Responsibility section of Bio-Techne's website.*Based on Scope 1 and 2 market-based greenhouse gas emissions.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at LinkedIn, X, or YouTube.Contact:Corporate Communications[email protected] David Clair, Vice President, Investor Relations [email protected] SOURCE Bio-Techne Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News